ETNB vs. SPRY, OPK, SAVA, ZNTL, INVA, ABVX, SAGE, ARCT, PLRX, and TNGX
Should you be buying 89bio stock or one of its competitors? The main competitors of 89bio include ARS Pharmaceuticals (SPRY), OPKO Health (OPK), Cassava Sciences (SAVA), Zentalis Pharmaceuticals (ZNTL), Innoviva (INVA), ABIVAX Société Anonyme (ABVX), Sage Therapeutics (SAGE), Arcturus Therapeutics (ARCT), Pliant Therapeutics (PLRX), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical preparations" industry.
89bio (NASDAQ:ETNB) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.
ARS Pharmaceuticals' return on equity of -22.24% beat 89bio's return on equity.
89bio currently has a consensus price target of $29.00, suggesting a potential upside of 225.11%. ARS Pharmaceuticals has a consensus price target of $18.50, suggesting a potential upside of 117.65%. Given 89bio's higher possible upside, analysts clearly believe 89bio is more favorable than ARS Pharmaceuticals.
ARS Pharmaceuticals has higher revenue and earnings than 89bio. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.
89bio received 85 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave ARS Pharmaceuticals an outperform vote while only 62.09% of users gave 89bio an outperform vote.
In the previous week, 89bio had 1 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 8 mentions for 89bio and 7 mentions for ARS Pharmaceuticals. 89bio's average media sentiment score of 0.43 beat ARS Pharmaceuticals' score of 0.20 indicating that 89bio is being referred to more favorably in the media.
68.2% of ARS Pharmaceuticals shares are held by institutional investors. 4.4% of 89bio shares are held by insiders. Comparatively, 35.6% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
89bio has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
Summary
ARS Pharmaceuticals beats 89bio on 9 of the 16 factors compared between the two stocks.
Get 89bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
